12:00 AM
May 28, 2012
 |  BC Week In Review  |  Company News  |  Deals

Active Biotech, Ipsen deal

Active Biotech said it received a €10 million ($12.8 million) milestone payment from partner Ipsen under a 2011 deal to co-develop and commercialize Active Biotech's tasquinimod. The milestone was triggered by...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >